Nivolumab纳武单抗纳武单抗,946414-94-4

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Nivolumab

CAS No. : 946414-94-4

MCE 国际站：Nivolumab

产品活性：Nivolumab 是一种 PD-1 人源类 IgG4 抗体类抑制剂，用于晚期（转移性）非小细胞肺癌的研究。

研究领域：Immunology/Inflammation

作用靶点：PD-1/PD-L1

In Vitro: Nivolumab binds to CHO cells expressing PD-1 with an EC₅₀ of 1.66 nM, but does not bind to the parental CHO cell line. Nivolumab binds to PD-1 on activated T cells with an EC₅₀ of 0.64 nM. Nivolumab also inhibits the interaction between PD-1 and its ligands, PD-L1 and PD-L2, with IC₅₀ values of 2.52 and 2.59 nM, respectively. Nivolumab (1.5 ng/mL) can enhance T-cell reactivity in the presence of a T-cell receptor stimulus.

In Vivo: Nivolumab (10 and 50 mg/kg, i.v.) is well tolerated in cynomolgus monkeys. Serum chemistry changes are limited to a reversible 28% decrease in T3 at week 13 in females treated with 50 mg/kg. T4 and TSH levels are unchanged. In males treated with 50 mg/kg, there are no changes in T3, T4, or TSH levels. Nivolumab exposure increases in an approximately dose-proportional manner between 10 and 50 mg/kg, with no substantial sex differences noted.

相关产品：Atezolizumab  |  Pembrolizumab  |  Cilengitide  |  BMS-1  |  BMS-202  |  JQ-1 (carboxylic acid)  |  Durvalumab  |  Tomivosertib  |  Avelumab  |  Anti-Mouse PD-L1 Antibody (10F.9G2)  |  Nivolumab (anti-PD-1)  |  Anti-Mouse PD-1 Antibody (RMP1-14)  |  Pembrolizumab (anti-PD-1)  |  Sulindac  |  CA-170  |  BMS-1166  |  INCB086550  |  Camrelizumab  |  Fraxinellone  |  Tislelizumab  |  PD-1/PD-L1-IN-9  |  BMS-8  |  Sintilimab  |  PD-L1-IN-1  |  Evixapodlin  |  PROTAC PD-1/PD-L1 degrader-1  |  Toripalimab  |  Onvatilimab  |  PD-1-IN-17

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds